Oncology · Colorectal CancerTrial Updateclinicalmid-term

Immune Profiling in dMMR/MSI-H CRC Reveals Prognostic Insights and Immunotherapeutic Potential

Importance8/ 10

ActionInvestigate

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/12/2026, 6:04:02 AM

Assessment confidence: 51% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

This study underscores the critical role of immune profiling in dMMR/MSI-H colorectal cancer, revealing significant prognostic insights that could reshape treatment strategies. The findings suggest that integrating immune profiling into clinical approaches may enhance patient stratification and optimize immunotherapy outcomes. Regulatory context from FDA (FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients) supports the near-term read. Assessment grounded in 12 ranked evidence items (1 high-relevance).

Strategic Assessment

The strongest clinical anchor is Bioelectrical Impedance Analysis for Perioperative Fluid Evaluation in Colorectal Cancer Surgery (ClinicalTrials.gov), sub-indication match (colorectal cancer). The integration of immune profiling could lead to more effective immunotherapy strategies, potentially increasing market share for companies that adapt their portfolios accordingly. This could also drive revenue growth through improved patient outcomes and treatment efficacy.

Competitive Pressure

The most relevant competitive pressure comes from These findings highlight the importance of immune profiling in CRC, which could influence treatment strategies and the development of immunotherapies in this patient population..

Regulatory Outlook

Regulatory risk is concentrated around As immune profiling becomes a more integral part of treatment strategies, regulatory bodies may require updated guidelines for clinical trials and approvals, impacting compliance and labeling for new therapies..

Key Risks

Elevated medium regulatory exposure for clinical trial sponsors could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.
Signal severity is high — leadership review is warranted.

Key Opportunities

The integration of immune profiling could lead to more effective immunotherapy strategies, potentially increasing market share for companies that adapt their portfolios accordingly. This could also drive revenue growth through improved patient outcomes and treatment efficacy.
Integrating immune profiling into clinical strategies for dMMR/MSI-H CRC to enhance patient stratification and optimize immunotherapy approaches.

What Would Change This Assessment

This becomes more urgent if Monitor developments in immunotherapeutic interventions targeting IDO1 and the incorporation of immune profiling in clinical trials for CRC.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source

Bioelectrical Impedance Analysis for Perioperative Fluid Evaluation in Colorectal Cancer Surgery
ClinicalTrials.govmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Liquid Biopsy for Early Detection of Colorectal Cancer Using Circular RNA
ClinicalTrials.govmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Colorectal Cancer Screening Outreach
ClinicalTrials.govmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
A Biomarker Exploration Study for Predicting Localization of Recurrence and Metastasis in Colorectal Cancer (PROBE Study)
ClinicalTrials.govmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
ClinicalTrials.govlow relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

No evidence in this category.

Immune evasion in locally advanced mismatch repair-deficient microsatellite instability-high colorectal cancer: Reduced T-cell infiltration and upregulation of epithelial IDO1 expression.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Altered crosstalk of bacterial lipopolysaccharide with immune cells in colorectal cancer compared to paired adjacent intestinal tissue.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Multi-omics analysis of saccharomyces boulardii supplementation reveals coordinated microbiome, metabolic, and immune signaling changes accompanying tumor suppression.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
The "oral-gut axis" transmission of microorganisms in colorectal cancer: Insights from Peptostreptococcus' perspective.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

clinical trial sponsors
dMMR/MSI-H colorectal cancer patients
oncology portfolio teams
immunotherapy developers

Commercial impact

high

The integration of immune profiling could lead to more effective immunotherapy strategies, potentially increasing market share for companies that adapt their portfolios accordingly. This could also drive revenue growth through improved patient outcomes and treatment efficacy.

Regulatory impact

medium

As immune profiling becomes a more integral part of treatment strategies, regulatory bodies may require updated guidelines for clinical trials and approvals, impacting compliance and labeling for new therapies.

What to watch

Monitor developments in immunotherapeutic interventions targeting IDO1 and the incorporation of immune profiling in clinical trials for CRC.

Recommended action

Investigate

Assign analyst review and cross-reference against active portfolio assets.

Signals